Buradasınız

Anasayfa » Content

Hepatit C virus infeksiyonunda yeni yaklaşımlar

New Approaches to Hepatitis C Virus Infection

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 1995

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Hepatitis C virus (HCV) is closely related to pestiviruses and flaviviruses. It was cloned from copy DNA (cDNA) extracted from infectious chimpanzee plasma in 1988. HCV is now recognized as the major causative agent for non- A, non-B hepatitis (NANBH). Based upon nucleic acid sequence analysis, six major HCV genotypes have been identifed worldwide. Enzyme-linked immunosorbant assays (ELISA), recombinant immunoblot assays (RIBA), synthetic peptide assays, polymerase chain reaction (PCR) are utilized for diagnosis. HCV may cause acute and chronic hepatitis, cirrhosis (CIR), hepatocellular carcinoma (HCC). The main route of transmission is parenteral, and most HCV-infected individuals are either IV drug users or recipients of blood products that in the past had not been screened for anti-HCV. Mother-to-infant transmission occurs in about 10% of HCV RNA positive mothers, mainly when maternal virus titers are high. Sexual transmission of HCV is probably absent or rare. There has not been HCV vaccine yet. Interferon is the only agent of proven efficacy in treatment of hepatitis C. The aim of this review is to revise new classification, genotypes, new diagnostic approaches and new treatment protocols about HCV.
Bookmark/Search this post with
Abstract (Original Language): 
Hepatit C virusu (HCV) pestiviruslar ve flaviviruslar ile yakından ilişkilidir. 1988'de infekte şempanzelerin plazmasından elde edilen copy DNA (cDNA)'dan klonlandı. HCV non-A, non-B hepatit grubunda major etkendir.Nükleik asit sequence analizleri temel alınarak tüm dünyada 6 büyük HCV genotipi tanımlanmıştır. Tanıda enzim-linked immunosarbant assays (ELISA), rekombinant immunoblot assays (RIBA), sentetik peptid assays, polimeraz zincir reaksiyonu (PCR) kullanılır. HCV akut ve kronik hepatit, siroz (CIR), hepatoselüler karsinom (HCC) meydana getirebilir.Ana bulaşma yolu parenteraldir ve diğer HCV infekte kişilerin çoğu İV ilaç kullananlar veya geçmişte anti-HCV antikorları bakılmadan kan ürünlerini kullananlardır. HCV pozitif annede virus titresi yüksek ise anneden fetusa geçiş oranı %10 civarındadır. Seksüel geçiş nadir veya yoktur. HCV aşısı henüz bulunamamıştır. Interferon tedavide kullanılan tek ilaçtır. Bu derlemeninin amacı HCV hakkında yeni sınıflandırma, genotipler, yeni tanı yaklaşımları ve tedavi protokollerini gözden geçirmektir.
FULL TEXT (PDF): 
PDF icon arastirmax-hepatit-c-virus-infeksiyonunda-yeni-yaklasimlar.pdf
  • 4
383-390
  • Turkish

REFERENCES

References: 

1 Choo Q-L, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-13 viral hepatitis genome. Science 1989; 244: 359¬62.
2. Cees L van der P, CuypersHT, Reesink HW. Hepatitis C virus six years on Lancet 1994. 344: 1475-1479
3. Grakowi A, Wychowski C, Lin C, et al. Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol. 1993; 67: 1385-95.
4 Weiner AJ, Gevşen HM. Christopherson C, et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential roie in chronic HCV infection. Proc Natl Acad Sci USA 1992; 89: 3468-72.
5 Simmonds P. Alberti A, Alter HJ, et al. A proposed system for the nomenclature of hepatitis C viral genomes. Hepatology 1994, 19: 1321-24.
6. Cees L van der P, Cuypers HT, Reesink HW, et al. Confirmation of hepatitis C virus infection by second generation four-antigent recombinant immunoblot assay and polymerase chain reaction. Lancet 1991; 337: 317-19.
7. Shimizu YK, Iwamato A, Hijikata M, et al. Evidence for in vitro replication of hepatitis C virus genome in a human T-cell line. Proc Natl Acad Sci USA 1992; 89: 5477-81
8. Lai ME, Mazzoleni AP. Argiolu F, et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 1994, 343.388-90.
9. Courouce MA, Bouchardeu F, Giroult A, et al. Significance of NS3 and NS5 antigens in screening for HCV antibody . Lancet 1994; 343. 853-854.
10. Busch MP, Tobler LH, Francis BS, et al. Reinstatement of donors who test false-positive in second-generation hepatitis C virus enzyme immunoassay should awant availability of licensed third-generation tests Transfusion 1994; 34: 130-34.
11. Alberti A, Morsica G, Chemello L, et al. Hepatitis C viremia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992; 340: 697-98.
12. Zaaijer HL, Cuypers HT, Reesink HW, et al. Reliability of polymerase chain reaction for detection of hepatitis C . Lancet 1993; 341: 722-24.
13. Lin HJ, Mizokami M, Hollinger FB. Polymerase Chain Reaction Assay for hepatitis C virus RNA using a single tube for Reverse Transcription and serial rounds of amplification with nested primer pairs. J Medical Virology, 1992, 33: 220-225.
14 Tilston P. Morris PJ. Klapper PE, et al. Commercial assay for hepatitis C virus RNA. Lancet 1994; 344: 201-02.
Journal of Turgut Özal Medical Center 2(4): 1995
New approaches to hepatitis C virus infection
15. Cha TA, Beall E, Irvine B, et al. At least five releaied but, distinct hepatitis C viral genotypes exist. Proc Natl Acad Sci USA 1992: 89: 7144-48.
16. McOmish F. Chan SW, Dow BC, et al. Detection of three types of hepatitis C virus in blood donors, investigation of type-specific differences in serologic reactivity and rate of ALT abnormalites. Transfusion 1993; 33: 7-13.
17. Okamoto H, Sugiyama Y, Okado S, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J General Virol 1992. 73. 673-79.
18. Simmonds P, McOmish F, Chan SW, et al. Sequence variability in the 5' non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence divesty. J General Virol 1993;74:661-68.
19. Simmonds P, Holmes EC, Cha TA, et al. Classification of hepatitis C virus into six major genotypes and series of subtypes by phylogenetic analysis of the NS5 region. J General Virol 1993; 74: 2391-93.
20. Stuyver L, Rossau R, Wyseur A, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J General Virol 1993; 74: 1093-1102.
21. Okamoto H, Okada S, Sugiyamu Y, et al. Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction (PCR) with two pairs of primers deduced from the 5'-noncoding region. Japanase J Experimental Medicine 1990; 4: 215-222.
22. Simmonds P, Zhang LQ, Watson HB, et al. Hepatitis C quantification and sequencing in blood products, haemophiliacs, and drug users. Lancet 1990: 336 (8729): 1469-72.
23. Kaneko S, Murahamı S, Unoira M, et al Quantitation of hepatitis C virus RNA by competitive polymerase chain reaction. J Medical Virol 1992, 32: 278 83
24. Ishiyama N, Katayama K, Ishimi N, et al. Quantitative analysis of hepatitis C virus by multicyclic RT-PCR. Japanase J Gastroenterol 1992; 6: 1396.
25. Kievitis T, van Gemen B, van Strijp D, et al. NASBA isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection . J Virological Methods 1991; 35: 273-286.
26. Urdea M. Synthesis and characterization of branched DNA (bDNA) for the direct and quantitative detection of CMV, HBV, HCV, and HIV. Clinical Chemistry 1993; 39(4): 720.
27. Urdea M (1994). Hepatitis C virus In Wright T. Bodenheimer JrHC ( Chairpersons)" " American Association for the study of liver diseases,
389
Hepatit C virus infeksıyonunda yeni yaklaşımlar
E Sönmez
Postgraduate course, Viral hepatitis A to F an update Chicago Illinois, pp 193-224.
28. Holmes EC. Simmonds P. Cha TA, et al (1994). Derivation of a rational nomenclature for hepatitis C virus Dy phylogenetic anaiysis of the NS5 region. In Nıshıoka K. Suzuki H, Mıchıro S. Oda T (eds) " Vırai hepatitis and liver disease Tokyo: Springer-Verlag press pp 57-62.
29 Alter HJ (1994) Hepatitis C: natural history. In Wright T Bodenheimer JrHC ( Chairpersons) " American Association for the study of liver diseases, postgraduate course Viral hepatitis A to F: an update Chicago, Illinois, pp 229-238.
30. Farci P, Alter HJ, Govindarajan S et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992; 258: 135-40.
31. Koziel MJ, Dudley D, Wong JT, et al. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 1992; 149: 3339-3344.
32 Esteban Jl. Lopez JC, Genesca J. et al. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Intern Med 1991: 115 443-49.
33 Michel g, Ritter A, Gerken G. et al. Anti-C or and hepatitis C virus in autoimmune liver diseases. Lancet 1992; 339: 267-69.
34. Gary LD(1994). Hepatitis C therapy. In Wright T, Bodenheimer HC (Chairpersons): " American Association for the study of liver diseases, Postgraduate course, Viral hepatitis A toF, an update" Chicago, Illinois, pp 247-254.
35 Lindsay KL, Davis GL, Schiff E, et al Long-term response to higher doses of interferon (IFN) alpha 2b treatment of patients with chronic hepatitis C: a randomized controlled multicenter trial. Hepatology 1993; 18: 106A.
36 Jowet P Roudot TF, Dhumeaux D. et al
Comperative efficacy of interferon alpha in cirrhotic and noncirrhotic patients with non-A, non-B C hepatitis Gastroenterol 1994 106: 686-90.
37. Beloqui O, Pricto J, Suarez M . et al N-acetyl cysteine enhances the response to interferon alpha in chronic hepatitis C: a pilot study. J Inerferon Res 1993, 13: 279-82
38 Kahumu S, Yoshiako K, Ishikawa T et al. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C Gastroenterol 1993; 105: 507-12.
39 Liaw YF. Sheen IS. Lin Su, et al Effects of prednisolone pretreatment in interferon alpha therapy for patients with chronic non-A, non-B (C) hepatitis. Liver 1993; 13: 46-50.
40 Camps J, Garcia N, Riezu Jl, et al. Ribavirin in the treatment of chronic hepatitis C unresponsive to alpha interferon. Hepatol 1993; 19: 408-12
41 Viladomiv L, Genesca J, Esteban Jl et al. Interferon alpha in acute postransfusion hepatitis C a randomized controlled trial. Hepatol 1992: 15: 767¬69.
42 Lampertico P, Rumi M, Romeo R, et al A multicenter randomized controlled trial of recombinant interferon alpha 2b in patients with acute transfusion-associated hepatitis C. Hepatol 1994; 19: 19-22.

Thank you for copying data from http://www.arastirmax.com